Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial

Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal antibody approved in several countries for the add-on maintenance treatment of patients with severe eosinophilic asthma aged 12 years and older. In the 28-week Phase III ZONDA trial (ClinicalTrials.gov identifier: NCT02075255)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ERJ Open Res
Main Authors: Menzies-Gow, Andrew, Corren, Jonathan, Bel, Elisabeth H., Maspero, Jorge, Heaney, Liam G., Gurnell, Mark, Wessman, Peter, Martin, Ubaldo J., Siddiqui, Shahid, Garcia Gil, Esther
Formato: Artigo
Idioma:Inglês
Publicado em: European Respiratory Society 2019
Assuntos:
Study Protocols
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6759576/
https://ncbi.nlm.nih.gov/pubmed/31579676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/23120541.00009-2019
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados